Phaseline

Companies › Mirum Pharmaceuticals

Mirum Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 11 registered trials: 6 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Gastroenterology, Infectious disease, Respiratory, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Maralixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 4Alagille Syndrome; Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC); Constipation Chronic IdiopathicFeb 2027
Brelovitug (BJT-778)
NTCP (sodium taurocholate cotransporting polypeptide) inhibitor
NTCPPhase 3Chronic Hepatitis D Infection; Chronic Hepatitis DJun 2027
Volixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 2Primary Biliary Cholangitis; Primary Sclerosing CholangitisJan 2027
[14C]-MRM-3379
unclear - FMRP pathway modulator for Fragile X Syndrome
–Phase 2Fragile X Syndrome; Healthy VolunteersOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07712718[14C]-MRM-3379Phase 1Healthy VolunteersOtherJul 2026
NCT05050136VolixibatPhase 2Primary Biliary CholangitisGastroenterologyJan 2027
NCT06553768MaralixibatPhase 3Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)GastroenterologyFeb 2027
NCT07200908Brelovitug (BJT-778)Phase 3Chronic Hepatitis D InfectionInfectious diseaseJun 2027
NCT06413368MaralixibatPhase 2Constipation Chronic IdiopathicRespiratoryJun 2027
NCT07454837Brelovitug (BJT-778)Phase 2Chronic Hepatitis DInfectious diseaseAug 2027
NCT07209462[14C]-MRM-3379Phase 2Fragile X SyndromeOtherOct 2027
NCT04663308VolixibatPhase 2Primary Sclerosing CholangitisGastroenterologyMar 2028
NCT07298330Brelovitug (BJT-778)Phase 3Chronic Hepatitis D InfectionInfectious diseaseJan 2029
NCT06907290Brelovitug (BJT-778)Phase 2Chronic Hepatitis D InfectionInfectious diseaseMay 2029
NCT07290257MaralixibatPhase 4Alagille SyndromeGastroenterologySep 2030

From the company's SEC filings

Cash and short-term investments of $374m on 2026-09-30; operating cash outflow about $372m a year; runway about 12 months at that burn, to Oct 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 15 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC10A2 (2) NTCP (1)

Companies with the same targets

GSK Albireo, an Ipsen Company

Companies built like this

Albireo, an Ipsen Company Inventiva Pharma Biocodex Beijing Continent Pharmaceutical Insmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.